HDAC inhibitor PAC-320 induces G2/M cell cycle arrest and apoptosis in human prostate cancer

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Histone deacetylase inhibitors (HDACis) exhibit significant antiproliferative effects across various cancers.
• Previous research identified polyoxometalate HDACis with antitumor potential using a p21 luciferase promoter system.

Purpose of the Study:

• To investigate the antitumor mechanism of PAC-320, a polyoxometalate compound, in human prostate cancer.
• To evaluate the efficacy of PAC-320 in inhibiting prostate cancer cell growth in vitro and in vivo.

Main Methods:

• Screening of polyoxometalate HDACis using a p21 luciferase promoter system.
• In vitro and in vivo studies to assess PAC-320's effect on prostate cancer cell growth.
• Analysis of cell cycle progression, apoptosis markers (p21, cyclin A, cyclin B1, Noxa, Hrk), and the p38 MAPK pathway.

Main Results:

• PAC-320 demonstrated broad-spectrum HDAC inhibition and suppressed prostate cancer cell growth.
• PAC-320 induced G2/M cell cycle arrest and apoptosis via the mitochondrial pathway.
• Upregulation of p21, Noxa, and Hrk, and downregulation of cyclin A and cyclin B1 were observed.
• The p38 MAPK pathway was implicated in PAC-320's antiproliferative activity.

Conclusions:

• PAC-320 exhibits potent in vitro and in vivo inhibitory activity against prostate cancer.
• The antitumor effects of PAC-320 are mediated through G2/M cell cycle arrest and apoptosis induction.
• PAC-320 represents a promising therapeutic candidate for prostate cancer treatment.